23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
20:49 , Mar 15, 2019 |  BioCentury  |  Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
20:07 , Mar 13, 2019 |  BC Extra  |  Financial News

BioNTech mum on $800M IPO report

Amid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options. Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz,...
00:31 , Jan 25, 2019 |  BC Week In Review  |  Company News

BioNTech acquiring MAB Discovery's antibody generation unit

BioNTech AG (Mainz, Germany) will acquire the antibody generation unit of MAB Discovery GmbH (Neuried, Germany) to expand its capabilities to rapidly produce new mAb candidates. BioNTech will gain all of MAB Discovery's assets, employees...
10:02 , Jan 23, 2019 |  BC Extra  |  Company News

BioNTech acquiring MAB Discovery's antibody generation unit

BioNTech AG (Mainz, Germany) will acquire the antibody generation unit of MAB Discovery GmbH (Neuried, Germany) to expand its capabilities to rapidly produce new mAb candidates. BioNTech will gain all of MAB Discovery's assets, employees...
18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
17:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

BioNTech to co-develop mRNA immunotherapy with Sanofi

BioNTech SE (Mainz, Germany) exercised an option under a 2015 deal to co-develop with Sanofi (Euronext:SAN; NASDAQ:SNY) an mRNA-based immunotherapy. Sanofi will make an €80 million ($91.5 million) equity investment in BioNTech. BioNTech said the...
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
15:45 , Jan 4, 2019 |  BC Extra  |  Company News

BioNTech to co-develop mRNA immunotherapy with Sanofi

BioNTech SE (Mainz, Germany) exercised an option under a 2015 deal to co-develop with Sanofi (Euronext:SAN; NASDAQ:SNY) an mRNA-based immunotherapy. Sanofi will make an €80 million ($91.5 million) equity investment in BioNTech. BioNTech said the...